Latest Impax Laboratories (IPXL) Headlines
Uptrend Call Working As Impax Laboratories Stock Rises 15.8% (IPXL)
Comtex SmarTrend(R) - Thu Mar 06, 9:29AM CST
SmarTrend identified an Uptrend for Impax Laboratories (NASDAQ:IPXL) on February 19th, 2014 at $24.01. In approximately 2 weeks, Impax Laboratories has returned 15.77% as of today's recent price of $27.79.
IHRDC's Ronnie Arnold Offers Seven Insights that Lead to Successful Adoption of Competency Management Systems
Business Wire - Tue Mar 04, 8:00AM CST
Ronnie Arnold, IHRDC Competency Development Product Manager, recently gave a presentation at the 2013 Getenergy VTEC Middle East/North Africa conference entitled "The seven strategies to incorporate a competency approach into your organization successfully." The talk, which was part of a panel discussion entitled "Workforce Competency Development," provided insights into the strategies used by some of IHRDC's clients to overcome the challenges of implementing and sustaining competency management systems.
Cabo Wabo(R) Tequila and Sixthman Keep the High Seas Rockin' with Legendary Music Moments
Business Wire - Tue Mar 04, 7:02AM CST
Music festivals at sea have never been more rock 'n' roll. For the fourth year in a row, Cabo Wabo(R), the original Rock 'n' Roll Tequila, is partnering with Sixthman, the industry leader in music festivals at sea, as a premier spirits partner for a series of rock focused music experience events. Legendary and rising star acts rocking the high seas on Sixthman and Cabo Wabo partnered music cruises include KISS, Lynyrd Skynyrd, Florida Georgia Line, Sister Hazel and Transatlantic.
Pernix to Market Osmotica's Khedezla - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 4:30PM CST
Pernix Therapeutics Holdings recently announced that it has signed an agreement with the privately-held Osmotica Pharmaceuticals Corp. to market major depressive disorder (MDD) drug Khedezla.
Patent Update from Mallinckrodt - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 27, 4:20PM CST
Mallinckrodt's Xartemis XR gains patent approval.
Impax Laboratories to Present at the Cowen and Company 34th Annual Health Care Conference
Business Wire - Wed Feb 26, 7:31AM CST
Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that Bryan M. Reasons, chief financial officer, will present a corporate overview at the Cowen and Company 34th Annual Health Care Conference on Monday, March 3, 2014 at 4:10 p.m. Eastern Standard Time. The conference will be held in Boston, MA.
Bacterin to Report Full Year and Fourth Quarter 2014 Financial Results on March 19, 2014
Business Wire - Tue Feb 25, 6:30AM CST
Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material and coatings for medical applications, today announced that it will release its financial results for the period ended December 31, 2013, on March 19, 2014 at the close of the financial markets.
Legal Settlement at Endo on Lidoderm - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 24, 10:30AM CST
Endo will have to shell out upto $194 million to settle the dispute on Lidoderm .
Impax Posts Loss in 4Q - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 21, 10:27AM CST
Impax reports loss in fourth quarter of 2013.
Impax Laboratories Reports Fourth Quarter and Full Year 2013 Results
Business Wire - Thu Feb 20, 3:01PM CST
--- Planning to Launch Authorized Generic RENVELA(R) (Sevelamer Carbonate) in April -
Impax Laboratories Shares Up 19.7% Since SmarTrend's Buy Recommendation (IPXL)
Comtex SmarTrend(R) - Fri Jan 31, 10:00AM CST
SmarTrend identified an Uptrend for Impax Laboratories (NASDAQ:IPXL) on May 29th, 2013 at $19.74. In approximately 8 months, Impax Laboratories has returned 19.74% as of today's recent price of $23.63.
Another Divestment at Actavis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 28, 3:45PM CST
Actavis has divested its Chinese subsidiary based in Foshan.
Impax Laboratories Up 26.2% Since SmarTrend Uptrend Call (IPXL)
Comtex SmarTrend(R) - Fri Jan 24, 9:30AM CST
SmarTrend identified an Uptrend for Impax Laboratories (NASDAQ:IPXL) on May 29th, 2013 at $19.74. In approximately 8 months, Impax Laboratories has returned 26.20% as of today's recent price of $24.91.
Impax Laboratories Schedules Conference Call and Webcast for Fourth Quarter and Full Year 2013 Financial Results
Business Wire - Fri Jan 24, 7:00AM CST
Impax Laboratories, Inc. (NASDAQ: IPXL) announced today that the Company will release its fourth quarter and full year 2013 financial results on Thursday, February 20, 2014, after the close of the U.S. financial markets. The Company will host a conference call and live webcast with the investment community at 4:30 p.m., Eastern Time on February 20, 2014.
Allergan Slips on Restasis Challenge - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 23, 12:50PM CST
Although Allergan's shares slipped slightly on the news regarding Actavis' ANDA, we do not expect generic competition to enter the market any time soon.
Mallinckrodt Up on FDA Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 21, 11:10AM CST
The company announced that Pennsaid 2% has been cleared by the FDA.
Impax's Outlook for 2014 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 16, 6:15PM CST
Impax provides financial guidelines for the current fiscal year.
FDA Panel Backs CHTP's Northera - Analyst Blog
Lopamudra Bhattacharya - Zacks Investment Research - Wed Jan 15, 5:10PM CST
FDA Panel Backs Chelsea Therapeutics International, Ltd.'s Northera.
Actavis Discusses Preliminary Q4 Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 15, 3:53PM CST
Actavis announced that it expects fourth quarter 2013 adjusted earnings to be slightly above the higher end of its previously guided range of $2.95 - $3.05 per share.
Uptrend Call Working As Impax Laboratories Stock Rises 15.8% (IPXL)
Comtex SmarTrend(R) - Thu Mar 06, 9:29AM CST
SmarTrend identified an Uptrend for Impax Laboratories (NASDAQ:IPXL) on February 19th, 2014 at $24.01. In approximately 2 weeks, Impax Laboratories has returned 15.77% as of today's recent price of $27.79.
IHRDC's Ronnie Arnold Offers Seven Insights that Lead to Successful Adoption of Competency Management Systems
Business Wire - Tue Mar 04, 8:00AM CST
Ronnie Arnold, IHRDC Competency Development Product Manager, recently gave a presentation at the 2013 Getenergy VTEC Middle East/North Africa conference entitled "The seven strategies to incorporate a competency approach into your organization successfully." The talk, which was part of a panel discussion entitled "Workforce Competency Development," provided insights into the strategies used by some of IHRDC's clients to overcome the challenges of implementing and sustaining competency management systems.
Cabo Wabo(R) Tequila and Sixthman Keep the High Seas Rockin' with Legendary Music Moments
Business Wire - Tue Mar 04, 7:02AM CST
Music festivals at sea have never been more rock 'n' roll. For the fourth year in a row, Cabo Wabo(R), the original Rock 'n' Roll Tequila, is partnering with Sixthman, the industry leader in music festivals at sea, as a premier spirits partner for a series of rock focused music experience events. Legendary and rising star acts rocking the high seas on Sixthman and Cabo Wabo partnered music cruises include KISS, Lynyrd Skynyrd, Florida Georgia Line, Sister Hazel and Transatlantic.
Pernix to Market Osmotica's Khedezla - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 4:30PM CST
Pernix Therapeutics Holdings recently announced that it has signed an agreement with the privately-held Osmotica Pharmaceuticals Corp. to market major depressive disorder (MDD) drug Khedezla.
Patent Update from Mallinckrodt - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 27, 4:20PM CST
Mallinckrodt's Xartemis XR gains patent approval.
Impax Laboratories to Present at the Cowen and Company 34th Annual Health Care Conference
Business Wire - Wed Feb 26, 7:31AM CST
Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that Bryan M. Reasons, chief financial officer, will present a corporate overview at the Cowen and Company 34th Annual Health Care Conference on Monday, March 3, 2014 at 4:10 p.m. Eastern Standard Time. The conference will be held in Boston, MA.
Bacterin to Report Full Year and Fourth Quarter 2014 Financial Results on March 19, 2014
Business Wire - Tue Feb 25, 6:30AM CST
Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material and coatings for medical applications, today announced that it will release its financial results for the period ended December 31, 2013, on March 19, 2014 at the close of the financial markets.
Legal Settlement at Endo on Lidoderm - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 24, 10:30AM CST
Endo will have to shell out upto $194 million to settle the dispute on Lidoderm .
Impax Posts Loss in 4Q - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 21, 10:27AM CST
Impax reports loss in fourth quarter of 2013.
Impax Laboratories Reports Fourth Quarter and Full Year 2013 Results
Business Wire - Thu Feb 20, 3:01PM CST
--- Planning to Launch Authorized Generic RENVELA(R) (Sevelamer Carbonate) in April -
Impax Laboratories Shares Up 19.7% Since SmarTrend's Buy Recommendation (IPXL)
Comtex SmarTrend(R) - Fri Jan 31, 10:00AM CST
SmarTrend identified an Uptrend for Impax Laboratories (NASDAQ:IPXL) on May 29th, 2013 at $19.74. In approximately 8 months, Impax Laboratories has returned 19.74% as of today's recent price of $23.63.
Another Divestment at Actavis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 28, 3:45PM CST
Actavis has divested its Chinese subsidiary based in Foshan.
Impax Laboratories Up 26.2% Since SmarTrend Uptrend Call (IPXL)
Comtex SmarTrend(R) - Fri Jan 24, 9:30AM CST
SmarTrend identified an Uptrend for Impax Laboratories (NASDAQ:IPXL) on May 29th, 2013 at $19.74. In approximately 8 months, Impax Laboratories has returned 26.20% as of today's recent price of $24.91.
Impax Laboratories Schedules Conference Call and Webcast for Fourth Quarter and Full Year 2013 Financial Results
Business Wire - Fri Jan 24, 7:00AM CST
Impax Laboratories, Inc. (NASDAQ: IPXL) announced today that the Company will release its fourth quarter and full year 2013 financial results on Thursday, February 20, 2014, after the close of the U.S. financial markets. The Company will host a conference call and live webcast with the investment community at 4:30 p.m., Eastern Time on February 20, 2014.
Allergan Slips on Restasis Challenge - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 23, 12:50PM CST
Although Allergan's shares slipped slightly on the news regarding Actavis' ANDA, we do not expect generic competition to enter the market any time soon.
Mallinckrodt Up on FDA Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 21, 11:10AM CST
The company announced that Pennsaid 2% has been cleared by the FDA.
Impax's Outlook for 2014 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 16, 6:15PM CST
Impax provides financial guidelines for the current fiscal year.
FDA Panel Backs CHTP's Northera - Analyst Blog
Lopamudra Bhattacharya - Zacks Investment Research - Wed Jan 15, 5:10PM CST
FDA Panel Backs Chelsea Therapeutics International, Ltd.'s Northera.
Actavis Discusses Preliminary Q4 Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 15, 3:53PM CST
Actavis announced that it expects fourth quarter 2013 adjusted earnings to be slightly above the higher end of its previously guided range of $2.95 - $3.05 per share.
